ANP1

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel allogeneic cell therapies for serious unmet medical needs. Its core technology, the AlloSCOPE™ platform, enables the scalable and consistent production of specialized human cells from pluripotent cell lines. The company is advancing multiple programs, including OPC1 for spinal cord injury and OpRegen for geographic atrophy, and has established a significant collaboration with Genentech. Lineage is publicly traded on the NYSE American under the ticker LCTX.

Therapeutic Areas